ORIC Pharmaceuticals Engages with Investors in February
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) is a dedicated clinical-stage oncology company that focuses on innovative treatments aimed at overcoming the challenges posed by therapeutic resistance in cancer. This month, ORIC Pharmaceuticals will engage with investors at several notable conferences, showcasing its commitment to advancing cancer treatment and enhancing investor relations.
Investor Conference Participation
During February, ORIC Pharmaceuticals will participate in a series of investor events designed to discuss its latest advancements and initiatives in oncology. These events present an opportunity for management to connect with investors and convey the company’s vision for addressing drug resistance in cancer.
Jones Research Precision Medicine Day
The first event is the Jones Research Precision Medicine Day, where ORIC Pharmaceuticals management will take part in a fireside chat on a specified date. This session will discuss critical developments in precision medicine and how ORIC's innovative therapies fit into this evolving landscape.
Guggenheim Securities SMID Cap Biotech Conference
Next up is the Guggenheim Securities SMID Cap Biotech Conference. The company will participate in another insightful fireside chat. This forum aims to highlight emerging opportunities in the biotech sector for small and mid-cap companies, and ORIC intends to showcase its strategic approach and scientific advancements.
Oppenheimer 35th Annual Healthcare Life Sciences Conference
Lastly, ORIC will attend the Oppenheimer 35th Annual Healthcare Life Sciences Conference. Management will discuss their pioneering strategies and product pipelines that are aimed at enhancing patient outcomes in difficult-to-treat cancers.
Live Streaming and Replay Information
Investors interested in following the discussions can access the live webcasts through the investor section of ORIC Pharmaceuticals' website. Replays will be available for 90 days after the events, ensuring that stakeholders can stay informed about the company's developments.
Insight into ORIC Pharmaceuticals
Founded with a mission to tackle the issue of therapeutic resistance in cancer, ORIC Pharmaceuticals is dedicated to the advancement of new therapies. Their innovative pipeline includes key candidates such as ORIC-114, designed to combat specific cancer mutations, and ORIC-944, which targets the polycomb repressive complex 2 (PRC2) for prostate cancer treatment.
The Impact of their Candidates
ORIC-114 is noted for its effectiveness against EGFR and HER2 anomalies, while ORIC-944 focuses on prostate cancer by targeting genetic markers associated with the disease. The company strives to bring novel solutions to patients battling cancer, underlining their commitment to addressing major medical challenges.
Company Locations and Operations
With offices in South San Francisco and San Diego, California, ORIC Pharmaceuticals leverages a robust base for its research and development endeavors. The company is poised to shape the future of oncology therapy through its innovative approaches and strong investor engagement.
Frequently Asked Questions
What are the key investor conferences ORIC Pharmaceuticals is attending?
ORIC Pharmaceuticals will participate in the Jones Research Precision Medicine Day, Guggenheim Securities SMID Cap Biotech Conference, and Oppenheimer Healthcare Life Sciences Conference.
Where can I view the live webcasts of these conferences?
The live webcasts will be available through the investor section of ORIC Pharmaceuticals' website.
What does ORIC-114 target?
ORIC-114 selectively targets EGFR exon 20 and HER2 exon 20 mutations in various cancer types.
What is the focus of ORIC-944?
ORIC-944 is an allosteric inhibitor of the PRC2 complex aimed at treating prostate cancer.
How long will the replays of the webcasts be available?
Replays of the webcasts will be accessible for 90 days following each event.